Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: cherry grove who wrote (2591)	11/7/1997 8:12:00 PM
From: Oliver & Co	of 6136

Hi Cherry, I am sorry I could not get to you before but I was attending the HIV Speakers Forum in Phoenix. Combivir is nothing else than azt and 3tc joint in the same pill. They should have done it before it improves compliance. Cryxivan is a good drug if you can take it, and adhere to the regimen. If you remember a couple of weeks ago, there was a lot of talk in this thread about resistance. And some people saying that 100% of patients will develop resistance to PIs. Well, at the conference Douglas Richmond, M.D. and others showed studies that after 2 years patients with complete virus suppression do not have genotipic(genetic), or phenotipic resistance to the virus. This had a lot to do with compliance. So we go back to the same, treatment is individualized, and the best treatment is the one that the patient can tolerate, and will adhere to. Good luck JLL

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next